|Author||: Benjamin Blass|
|Release Date||: 2015-04-24|
|ISBN 10||: 012411525X|
|Pages||: 580 pages|
Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, providing comprehensive explanations of enabling technologies such as high throughput screening, structure based drug design, molecular modeling, pharmaceutical profiling, and translational medicine, all areas that have become critical steps in the successful development of marketable therapeutics. The text introduces the fundamental principles of drug discovery and development, also discussing important drug targets by class, in vitro screening methods, medicinal chemistry strategies in drug design, principles in pharmacokinetics and pharmacodynamics, animal models of disease states, clinical trial basics, and selected business aspects of the drug discovery process. It is designed to enable new scientists to rapidly understand the key fundamentals of drug discovery, including pharmacokinetics, toxicology, and intellectual property." Provides a clear explanation of how the pharmaceutical industry works Explains the complete drug discovery process, from obtaining a lead, to testing the bioactivity, to producing the drug, and protecting the intellectual propertyIdeal for anyone interested in learning about the drug discovery process and those contemplating careers in the industry Explains the transition process from academia or other industries
This book is unique in covering the present status and future potential of natural products in drug discovery. It provides readers with recent information regarding the impact on drug discovery, development and strategies, technical and automation aspects, and methods based on biochemistry as well as molecular biology, highlighting compounds from natural sources. Special emphasis is placed on the various strategies to gain access to natural compounds and combinatorial approaches by making use of both synthetic and biological methods.
|Author||: Feng Wang|
|Publisher||: Springer Science & Business Media|
|Release Date||: 2008-03-11|
|ISBN 10||: 1934115231|
|Pages||: 396 pages|
In this book, expert researchers provide a tool box for those who have a general interest in biomarker research and for those currently specializing in certain technologies but desiring an understanding of other available methodologies. Its chapters include validated, mature methods as well as new, incredibly promising protocols. This book is the perfect biomarker technical guideline and reference to stimulate more exciting biomarker research and technology development.
|Author||: Ronald Borchardt,Edward Kerns,Christopher Lipinski,Dhrien Thakker,Binghe Wang|
|Publisher||: Springer Science & Business Media|
|Release Date||: 2005-12-05|
|ISBN 10||: 9780971176799|
|Pages||: 482 pages|
This volume focuses on how to increase the efficiency of drug discovery and development. It is written by experienced discovery scientists from diverse disciplines, including chemistry, drug metabolism, and development sciences. The volume details in silico, in vitro, and in vivo tools for prediction, measurement, and application of compound properties to select and improve potential drug candidates.
A collection of methods to determine and analyse the 3-D structure of biomolecules. These methods have been enhanced to improve the speed and quality of drug discovery.
|Author||: Hans Vogel|
|Publisher||: Springer Science & Business Media|
|Release Date||: 2007-10-30|
|ISBN 10||: 3540714200|
|Pages||: 2068 pages|
The new edition of this successful reference offers both cutting-edge and classic pharmacological methods. Thoroughly revised and expanded to two volumes, it offers an updated selection of the most frequently used assays for reliably detecting the pharmacological effects of potential drugs. Every chapter has been updated, and numerous assays have been added. Each of the more than 1,000 assays comprises a detailed protocol outlining purpose and rationale, and a critical assessment of the results and their pharmacological and clinical relevance.
This two volume set provides a comprehensive account of the entiresequence of operations involved in discovering a drug through theactual delivery of the drug to clinicians and medicalpractitioners. Includes case studies of the discovery of erythromycin analogs(antibiotics), Tagamet, and Ultiva (remifentanil) Discusses the discovery of agents for the treatment andmanagement of bacterial infections, Parkinson's disease, psoriasis,ulcers and stomach pain, atopic dermatitis, asthma, and cancer Contains chapters on combinatorial chemistry, molecularbiology-based drug discovery, genomics, and chemogenomics The first volume of this set thoroughly describesconceptualizing a drug, creating a library of candidates fortesting, screening those candidates for in vitro and in vivoactivity, conducting and analyzing the results of clinical trials,and revising the drug as necessary.
|Author||: Robert M. Stroud,Janet Finer-Moore|
|Publisher||: Royal Society of Chemistry|
|Release Date||: 2008|
|ISBN 10||: 0854043659|
|Pages||: 382 pages|
This insightful book represents the experience and understanding of the global experts in the field and spotlights both the structural and medicinal chemistry aspects of drug design. The need to 'encode' the physiological factors of pharmacology, a key area, is explored.
Research in the pharmaceutical industry today is in many respects quite different from what it used to be only fifteen years ago. There have been dramatic changes in approaches for identifying new chemical entities with a desired biological activity. While chemical modification of existing leads was the most important approach in the 1970s and 1980s, high-throughput screening and structure-based design are now major players among a multitude of methods used in drug discov ery. Quite often, companies favor one of these relatively new approaches over the other, e.g., screening over rational design, or vice versa, but we believe that an intelligent and concerted use of several or all methods currently available to drug discovery will be more successful in the medium term. What has changed most significantly in the past few years is the time available for identifying new chemical entities. Because of the high costs of drug discovery projects, pressure for maximum success in the shortest possible time is higher than ever. In addition, the multidisciplinary character of the field is much more pronounced today than it used to be. As a consequence, researchers and project managers in the pharmaceutical industry should have a solid knowledge of the more important methods available to drug discovery, because it is the rapidly and intelligently combined use of these which will determine the success or failure of preclinical projects.
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
This book is a landmark in the continuously changing world of drugs. It is essential reading for scientists and managers in the pharmaceutical industry who are involved in drug finding, drug development and decision making in the development process.
Mainly addressing parasitic diseases but also focusing on diseases caused by bacteria, this much-needed reference and handbook provides a unique insight into the approach adopted by commercial science towards infectious diseases, including the work of medicinal chemists. Many of the authors are scientists with hands-on experience of drug discovery units within the pharmaceutical industry. In addition, the text covers efforts towards drug development in infectious diseases from academic groups and non profit organizations.
This up-to-date summary of natural product chemistry in drug discovery will appeal to scientists, professionals, postgraduates and industrial chemists.
This edition provides expanded coverage of pre-20th century drugs, including emphasis on setting chapters in a wide historical and social context.
Exploring innovative routes of drug discovery in the postgenomic era, Microbial Genomics and Drug Discovery examines bioinformatic and genomic approaches for the identification, detection, selection, and validation of new antibacterial targets and vaccine candidates. The book discusses potential pathways for effective infection control, inhibition
Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs ‘work’ medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable? This book opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process. * Co-written by Graham Lees and Tamas Bartfai who has been involved in the development of drugs taken by more that 20 million people every day * Opens the windows and doors of the most regulated industry in the world, the pharmaceutical industry * Tells the story of drug development by using real examples based on current research and events * Provides an objective, lucid account of the successes and failures, shortcomings and constraints of the pharmaceutical and biotech industries * Gives insights into the development of new drugs to combat multiple conditions including cancer and pain * Balanced, unbiased account of how better to translate basic science into drug discovery
|Author||: Howard M. Fillit, MD,Alan W. O'Connell, PhD|
|Publisher||: Springer Publishing Company|
|Release Date||: 2002-01-03|
|ISBN 10||: 9780826115348|
|Pages||: 296 pages|
This prestigious volume presents the findings of an international group of academic and biotechnological researchers. Topics range from early detection programs focusing on genetic factors, novel probes for detecting B-amyloid in the living brain, and the use of telephonic screening and MRI's to the diversity of therapeutic areas such as antioxidants, estrogen agonists and various anti-B-amyloid and anti-tangle approaches. The volume is still an indispensable resource for the psychogeriatrician, psychiatrist, clinical investigator, and neurobiologist, and a must for medical libraries.
The Drug Discovery Handbook gives professionals a tool tofacilitate drug discovery by bringing together, for the first timein one resource, a compendium of methods and techniques that needto be considered when developing new drugs. This comprehensive, practical guide presents an explanation of thelatest techniques and methods in drug discovery, including: Genomics, proteomics, high-throughput screening, and systemsbiology Summaries of how these techniques and methods are used todiscover new central nervous system agents, antiviral agents,respiratory drugs, oncology drugs, and more Specific approaches to drug discovery, including problems thatare encountered, solutions to these problems, and limitations ofvarious methods and techniques The thorough coverage and practical, scientifically validproblem-solving approach of Drug Discovery Handbook will serve asan invaluable aid in the complex task of developing new drugs.
Navigate the complex and multidisciplinary path of drug discovery procedures with Drug Discovery Strategies and Methods-a well-organized and timely reference that analyzes methods in target identification and validation, lead detection, compound optimization, and biological testing. This volume addresses challenges encountered during the discovery of new pharmaceutical candidates including the use of cutting-edge techniques utilized in drug design and development. It considers key elements in the drug design cycle ranging from appropriateness of targets and disease models to compound characterization, safety, and efficacy and the role of protein crystallography in structure-based drug design.